HRT Got a Bad Reputation. Here’s What the Science Actually Says.
Millions of women stopped hormone therapy after a 2002 study changed the picture. The science has moved on significantly. Here’s what we actually know now.
If you’ve asked a doctor about hormone therapy in the last two decades, fear has probably entered the conversation at some point. Maybe your doctor mentioned cancer risk. Maybe your mother was told to stop HRT years ago and never went back on. Maybe you’ve heard enough conflicting things that the uncertainty itself has felt like a reason to avoid it.
I’ve heard a version of this from patients regularly. And I understand it. But I want to give you the full picture of where the science actually stands — because the fear most women are carrying is based on data that has been substantially reinterpreted since it was first published.
Where did the fear about hormone therapy come from?
In 2002, the Women’s Health Initiative — a large federal study examining hormone therapy in postmenopausal women — published results that sent shockwaves through medicine. The study reported increased risks of breast cancer, heart disease, stroke, and blood clots in women taking a specific combination of synthetic estrogen and progesterone.
Hormone therapy prescriptions dropped dramatically almost overnight. Women stopped their medications. Physicians became reluctant to prescribe. The conversation about menopause care shifted from treatment to endurance.
The problem is that the WHI study had significant limitations that were never adequately communicated to the public.
The average age of participants was 63 — more than a decade past the average age of menopause onset. These were not women in perimenopause or early menopause. Many had gone years without estrogen before starting the study. The biology is different in that population, and the risks are different too.
They studied a progestin called medroxyprogesterone acetate, a synthetic compound that behaves differently from bioidentical progesterone, which is what is most commonly used in modern hormone therapy. And the study combined results from different participant groups in ways that made it difficult to distinguish the effects of estrogen alone from estrogen-progestin combinations — which have meaningfully different risk profiles.
When researchers re-analyzed the WHI data with more nuance in subsequent years, the picture changed substantially. For healthy women under 60, or within 10 years of menopause onset, the risk profile of hormone therapy looks very different from what the original headlines suggested.
What does the science say now about HRT safety?
For appropriately selected women in perimenopause or early menopause, hormone therapy has a favorable benefit-risk profile. The increased cardiovascular risk that dominated the 2002 headlines largely disappears in this population. The breast cancer risk, when it exists, is small — researchers have contextualized it as comparable to the risk associated with drinking a glass of wine per day or being sedentary.
Hormone therapy is the most effective treatment available for hot flashes and night sweats. It addresses sleep disruption, mood changes, brain fog, and vaginal symptoms. It supports bone density and reduces fracture risk. When initiated close to menopause onset, it has evidence for cardiovascular benefit. Emerging research continues to examine its role in long-term cognitive health.
The specific risk picture depends on individual factors: the type of hormones used, the delivery method, the dose, the timing of initiation, and a woman’s personal health history. Transdermal estrogen carries lower risk of blood clots than oral formulations. Bioidentical progesterone has a different risk profile than synthetic progestins. These distinctions matter and should be part of any individual evaluation.
Did the FDA change its position on hormone therapy?
Yes. In late 2025, following a full review of the updated evidence, the FDA removed the black box warning that had been on estrogen products since the WHI findings were published. That warning had persisted for more than two decades despite the evolving science — a regulatory lag that affected how physicians counseled patients and how women understood their options.
The removal reflects the current scientific consensus: for appropriately selected women, hormone therapy is not the dangerous intervention it was portrayed as in 2002.
What does this mean if you’ve been avoiding hormone therapy?
If you were told that hormone therapy was too risky and you’ve been managing without it, a fresh conversation with a provider who is current on the evidence is worth having. What you were told may not reflect where things stand today.
If you’re in perimenopause now and wondering whether hormone therapy is an option, the answer for many women is yes — and the conversation should start with an honest assessment of your individual risk factors, your symptoms, and your goals. Not with a reflexive refusal based on decades-old headlines.
There’s a generational piece to this too. Women who were told to stop HRT in 2002 watched that happen. Their daughters absorbed the fear even without living through it. Reversing that takes more than updated guidelines — it takes providers willing to have a real, evidence-based conversation instead of defaulting to caution.
What we still don’t know
Being honest about the evidence means acknowledging its limits. Long-term data on some newer formulations is still developing. Individual variation is real — not everyone responds the same way, and not everyone is a candidate. Women with certain hormone-sensitive cancers or clotting disorders have contraindications that must be taken seriously.
Good hormone care is individualized. It starts with a thorough evaluation, involves honest conversation about tradeoffs, and adjusts based on how you respond. That’s what the evidence supports — not fear, and not a one-size-fits-all answer in either direction.
Dr. Jessica Duncan is the Chief Medical Officer at Ivim Health, a physician-led virtual metabolic health company operating across 49 states. She is board-certified in obesity medicine and has published peer-reviewed research on GLP-1 outcomes in Obesity Pillars.
Disclaimer:
Medical Advice: This content is for informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider regarding your health needs, diagnosis, and medication management.
